Top Healthcare & Digital Health + Biotech & Life Sciences Investors 2026

Healthcare's largest markets are ripe for disruption through software-first solutions. We back companies advancing care delivery through new technologies and care models, and software-first techbio platforms that transform drug discovery and therapeutic development.

Back exceptional inventors building their own enduring businesses in life sciences. Founders who design the initial conditions of a company have superior odds of creating transformative value.

Transforming disruptive European academic research into innovative therapeutics and diagnostics for severe diseases with high unmet medical needs. Operates as a venture builder, co-founding companies ex-nihilo from scientific discoveries and backing established venture-stage biotechs.

Funds founders elevating brain and mental health through neuroscience, frontier technologies, psychedelic medicine, precision neuroscience, neurotechnology, AI-enabled diagnosis and treatment, novel CNS therapeutics, digital health, and related modalities.

We invest in people solving difficult problems and building category-defining products in healthcare. We partner with visionary leaders at the intersection of medical technology and digital health to create transformative solutions that improve patient outcomes.

Invest in early-stage digital health companies that empower informed, connected health consumers to make confident decisions about their health. Focus on removing friction from healthcare, providing transparency, and enabling people to take control of their health journey through technology. Particular emphasis on solving structural problems in chronic disease management, mental health, reproductive health, aging in place, and specialty care navigation.

CVS Health Ventures invests in healthcare innovators that make care simpler, more accessible, and more affordable. The fund leverages CVS Health's national footprint — 9,000+ pharmacies, MinuteClinics, Aetna, and Oak Street Health — as a strategic distribution channel and operating partner for portfolio companies. Key focus areas: tech-enabled clinical workflows, disruptive care models, whole-person health, and consumer-centric experiences.

Inflect Health invests in visionary entrepreneurs building category-defining solutions to transform healthcare. Unlike traditional VCs, Inflect's success metric balances financial returns with health outcomes improvement. We back founders with clear vision, diverse teams, and passion for healthcare transformation. Our physician-led partnership brings 45+ years of healthcare operational expertise and direct access to 8,000+ clinicians, enabling hands-on partnership from design through go-to-market.

Deep health emerges at the convergence of advances in biology, chemistry, AI/ML, robotics, and clinical medicine. We back visionary founders addressing root causes of chronic disease across three domains: biology within us (biotech platforms), environment around us (environmental/chemical health), and systems that care for us (healthcare delivery innovation).

Fund and build next-generation life sciences companies solving important healthcare needs through cutting-edge breakthroughs in medicine and science. Partner closely with management teams to maximize returns across all portfolio companies through hands-on operational support, strategic guidance, and access to networks of experienced life science leaders.

Talented early-stage biotech founders need patient capital and experienced mentorship to navigate the intersection of genomics and data science. We provide both financial support and hands-on operational guidance from day one.

Healthcare is one of the most compelling long-term investment opportunities globally, driven by aging demographics, rising healthcare spending, and continuous scientific innovation. We invest across the entire healthcare value chain to drive innovation and address unmet medical needs.

Breakthrough science merged with operational rigor creates transformational opportunities in life sciences. We identify emerging fields at the intersection of science and unmet medical need, then actively shape company formation working with scientific founders and expert advisors to design strategy from inception.

Early-stage companies leveraging frontier technologies (AI, gene editing, synthetic biology, advanced diagnostics) to transform human health, cure disease, and strengthen global resilience. Data-driven, engineering-first approaches combined with cellular biology create transformative healthcare companies. Focus on companies that solve problems affecting everyday people globally with platform potential across multiple indications and therapeutic pathways.

Translating groundbreaking science into life-changing medicines through seed-led investment model emphasizing science-first, patient-centric, collaborative approach. Play the long game with urgency - combining patient discipline with speed to market.

Healthcare innovation is a team sport. We identify promising healthcare technologies early in their life cycle and invest much more than capital to help our teams become world-class enterprises. We provide clinical expertise, operational guidance, and network access from a team of practicing physicians and healthcare operators.

Science-backed sleep solutions will dominate the market. We invest in innovative solutions across all sectors aimed at improving sleep, applying advanced sleep science to support portfolio companies.

Life sciences is experiencing unprecedented innovation through TechBio—companies that merge technology and biology. We partner with passionate, accomplished founders with unique insights to solve daring life science problems and significantly impact patient care. We provide capital, operational support, scientific guidance, and industry relationships to build transformative companies.

Back global-minded founders with cross-cultural perspectives and lived experience solving structural healthcare inequities. We invest at the intersection of clinical expertise and technical execution, deploying human capital, financial capital, and cultural capital to support founders building solutions that improve patient outcomes, lower costs, enhance patient and provider experience.

Systematically back clinically rigorous, behaviorally grounded wellbeing startups tackling stigmatized areas—alcohol use disorder, menopause, mental health—using stigma as an investing edge and insisting on consumer-grade UX. Solve the Wellness Gap: the quantifiable delta that has grown as GDP per capita increased while physical and mental health stagnated.

Invest in visionary technical founders building frontier healthcare solutions at the intersection of novel science and deep technology. Focus on 'hard problems' requiring scientific innovation and engineering excellence—neurotech, AI-driven biology, AR/VR medical applications, and novel care delivery models. Partner with founders (especially scientists and engineers from academia transitioning to entrepreneurship) who are fundamentally changing how healthcare works.

Investing in healthcare data companies tackling the biggest problems in cancer care — from early detection to patient navigation to data access and AI-powered treatment optimization. The U.S. oncology system is fragmented, expensive, and filled with barriers to evidence-based care. We fund the technologies that fix this.

Venture capital can do more than fund companies—it can create them from the ground up. Newpath Partners specializes in building biotechnology companies in partnership with leading academic scientists, focusing on breakthrough biology platforms in gene editing, regenerative medicine, and transformational therapeutics that address the greatest unmet medical needs.

Co-found and build breakthrough life sciences and deep-science companies with university researchers. Follow science to create revolutionary technologies that prevent, detect, and cure disease. Patient capital from concept stage through commercialization.

Breakthroughs at the convergence of technology, science, and humanity improve how we live, work, and experience the world. We invest in transformative technologies for human performance and wellbeing.

Science-driven venture capital focused on breakthrough healthcare innovations. Deep scientific rigor in diligence with mechanism-of-action understanding, proof-of-concept validation, and extensive KOL/clinician engagement. Backed by Zambon Group pharmaceutical expertise.

Back transformational healthcare companies at pre-seed through Series A that leverage technology to improve patient outcomes, healthcare operations, or clinical delivery. Partner with founders who understand both healthcare workflows and technology innovation deeply.

The best healthcare solutions emerge from teams that deeply understand real-world clinical challenges. We embed 650+ clinicians as partners in deal sourcing, diligence, and portfolio support. Unlike traditional VCs, we connect founders with authentic practitioners who understand unglamorous but deeply human healthcare problems.

Healthcare's future will be defined by the convergence of technology innovation, consumer preferences, and industry transformation. We partner with entrepreneurs who combine deep healthcare domain expertise with technical excellence to build category-defining companies.

Complex health problems require multidisciplinary teams combining deep technical, financial, and domain expertise. We invest in breakthrough science and technology-enabled solutions across human and animal health.

Civilization Ventures backs exceptional scientific founders—particularly PhDs and postdocs from elite institutions—building essential innovations in health tech and biology. We believe the best breakthroughs come from disruptive science combined with founder determination. We provide 'mentor capital': not just capital, but active operational guidance, scientific rigor, and access to our network of Fellows, Advisors, and portfolio founders.

Longevity is a completely new industry within biotech requiring founders who can think differently. Mission-oriented, founder-led companies with unconventional backgrounds will prove most effective at bringing the first longevity drugs to market and extending human healthy lifespan. The field is at a critical inflection point where we will either breakthrough to mainstream or get silo'd in a funding winter.

Create first-in-category bioplatform companies through scientific innovation and systematic entrepreneurship. Combine institutional scale with pioneer creativity to build breakthrough life sciences companies.

Partner with mission-oriented founders working on transformational ideas that use science and technology to improve human health and better humanity in lasting ways. We seek founders who bring deep technical expertise and commitment to solving complex scientific and healthcare challenges.

Funding the next generation of contrarian founders building breakthrough longevity biotech companies. We invest in the transition from sickcare to healthcare by extending healthy lifespan and preventing age-related disease.

Technology and biology are converging to create the next generation of transformative companies. The digitization of life sciences—driven by exponential growth in biological data and advances in AI/ML—is enabling a new class of platform companies that will dominate the industry. Tomorrow's biotech will be built by teams of three: a biologist, a chemist, and a computer scientist.

Apply revolutionary biotechnology to replace industrial inputs with biology-based alternatives, transforming how the world manufactures chemicals, materials, foods, and medicines. Synthetic biology is a $25T opportunity spanning industrial inputs, food & agriculture, pharmaceuticals, and specialized applications.

Mission-driven founders building transformative companies. FPV backs missionaries, not mercenaries—founders with genuine conviction in solving hard problems and willingness to pursue 100-year visions. Focus on founders who are misunderstood initially but recognized as geniuses for changing the world. Founder service is their North Star—they aim to be the founder's first phone call with operational support from experienced partners.

Contrarian venture firm investing in scientific and technical breakthroughs. We identify white-space opportunities where technical founders are solving previously unsolvable problems. We combine capital with deep domain expertise, research capabilities, and operational support to help founders scale from idea to commercialization.

Backing transformative founders building exceptional companies across all sectors

Synthetic biology and life sciences are engineering disciplines. The world's greatest challenges in human and planetary health will be solved by scientists and engineers using biology as a tool. We fund the earliest-stage founders with breakthrough ideas and provide wet lab infrastructure, capital, and long-term partnership.

Back ambitious 'go-all-in' founders building defensible B2B software at pre-seed and seed, and support them intensively through the journey to Series A. Focus on AI, infrastructure, health, TechBio, open source, and marketplaces.

Atinum Investment identifies and invests in companies solving fundamental problems through technology innovation and market disruption. The firm specializes in growth-stage startups and paradigm-shifting companies across diverse sectors.

Passion and vision matter more than pedigree. We seek founders with grit, audacity, and a spark of rebellion—regardless of background. We invest early, before success is inevitable, and support founders from 0-to-1 through Series A.

Identifying culturally resonant, consumer-focused companies with differentiated products and founder teams that will capture global attention. We invest across technology, consumer behavior, entertainment, and culture—seeking to spot emerging trends before they reach mainstream awareness. We operate as a partnership combining rigorous deal selection with exceptional founder support, creative marketing, and deep understanding of consumer psychology.

Thesis-driven early-stage venture capital firm investing in visionary founders building transformative technologies in Vertical AI, Deep Tech, Healthcare, and Biotech. Focus on companies built on defensible data moats and novel technological breakthroughs solving fundamental problems. Emphasis on long-term value creation and partnership from day zero. Rapid decision-making (10-15 business days) combined with hands-on operational support. NPS score of 100 from portfolio founders.

The most enduring companies are created by founders willing to commercialize real science and scale real systems. We focus on hard tech at the intersection of computation and physical sciences—aerospace, biotech, energy, materials—where technical execution is the moat.

Data, cloud, and hardware advances will create unprecedented opportunities for great companies to be built. We invest in founders with big ideas and deep tech who are building infrastructure and value chains around data. Great people are the key to company success. We provide operational expertise, strategic guidance, and access to networks of mentors and international partners, particularly in China and Asia-Pacific.

Founders backed by entrepreneurs. ZAKA bridges North American and CEE startup ecosystems, investing pre-seed to seed in Health & Biotech and Industrial Tech. The firm deploys institutional capital while leveraging operator networks to help European founders scale globally.

Mission-driven companies solve big problems at scale while building durable competitive advantages. We back founders leveraging science & technology to build the Better Economy where people and planet thrive.

The era of transformational science is here. Life sciences and industrial markets are being reshaped by founders who move fast and build at the intersection of biology, chemistry, computation, and AI. This is a step-change in how science becomes solutions. We back bold founders who go beyond solving technical problems to redefine entire markets.

Invest with conviction in visionary, technical founders inventing the future with frontier computing technology. Focus on computing×real-world startups (techbio, climate, robotics, industrial infrastructure). Enforce strict rebuildability bar—won't invest if 3-5 Google engineers could recreate product in 3-12 months. Position against SaaS/consumer playbook; future venture outliers will be very different.

Expertise unlocks AI's full potential. We back technical founders who harness deep domain knowledge, apply novel AI applications, and push boundaries to create transformative breakthroughs in healthcare, life sciences, and enterprise.

We invest in the future of food — backing game-changing early-stage ventures (Pre-Seed to Series A) that redefine how consumers achieve health and wellness across the entire food value chain: high-growth consumer brands, proprietary foodtech, next-gen commerce, and value-add digital technology. Fund III ($45M, 2024) emphasizes nutrition, sustainability, and digitization, with a thematic focus on food-as-medicine.

Artificial intelligence will reshape every industry. We partner with technical founders building the next generation of AI applications, infrastructure, and tools across every layer of the AI stack.

The biggest companies of the century will be built solving the world's most pressing problems. We champion ambitious founders using technology to reshape civilization around climate, health, and inclusive capitalism.

Olive Tree Capital invests in groundbreaking technology and life sciences companies guided by the Golden Rule philosophy. As an evergreen vehicle without asset class limitations or holding period constraints, OTC can be a long-term partner to founders across any stage and geography.

Pre-seed fund investing in technical founders building developer-facing tools and infrastructure. Focused on curiosity, velocity of learning, and rapid building. Believe the world is shaped by unique insights at the intersection of art/culture and math/science.

Biology is the next frontier of technology. BABEL believes early-stage consumer biotech can solve macro problems (food security, climate, health) while delivering outsized returns. The best outcomes come from diverse, science-credentialed founder teams with deep domain expertise and commitment to sustainability and impact.

Disruptive innovation in work and education fuels human achievement. We partner with exceptional entrepreneurs who are business builders, deep domain experts, and capital efficient thinkers. We believe in long-term relationships over transactional investing, often partnering with founders across multiple ventures.

Early-stage innovation from founders backed by seasoned operators. We invest in disruptive technologies solving real problems at the intersection of scientific breakthroughs and practical execution. Our founders get patient capital, hands-on mentorship from 100+ years of combined experience, and access to our network for strategic growth.

Unearth, invest and grow startups into global leaders. iGlobe targets game-changing innovations at the frontier of deep tech — semiconductors, AI, quantum computing, and biotech — with a global orientation and a Singapore hub. Founded by Soo Boon Koh, Singapore's first female VC, the firm brings 25+ years of cross-border investing expertise and a top-quartile performance record.

Backs deep-tech founders who pair technical ambition with decisive execution. Invests in frontier technologies before they become mainstream across aerospace/defense, healthcare, biotech, enterprise AI, and deep hardware. Active partner model — regulatory introductions, customer connections, and strategic guidance through all company phases.

Backing dynamically developing enterprises with global aspirations at seed and early stage across Internet/SaaS, IoT/Hardware, Renewable Energy Sources, and Life Science (MedTech/BioTech). 4-14 year investment horizon with a patient capital approach through multiple fund vehicles.

Make no little plans. Support revolutionary (not evolutionary) ideas that transform industries and benefit society. We partner with entrepreneurs solving massively multi-disciplinary problems at the intersection of AI, data, biotech, and deep tech. Our style of in-the-trenches venture capital doesn't scale—we make fewer than 10 investments per year so we have time to roll up our sleeves with every team we back.

Invest in science-led consumer companies using a rigorous '12+ months to replicate' defensibility test. We back founders creating genuine technological moats by applying rigorous science to solve real consumer problems, with special focus on underrepresented founders (80% of portfolio).

Madrona invests in people and ideas for the long run — backing visionary founders building transformational technology companies, with deep focus on applied AI across domain-specific applications, AI infrastructure, developer tools, enterprise software, and AI-enabled biotech. The firm serves as an active, full-stack partner providing capital plus recruiting, business development, and customer introductions.

We back deeply technical founders solving hard problems with innovative technologies. Combining capital with go-to-market expertise and structured fellowships, we partner with founders who have authentic personal connections to their problems and bring novel technological approaches to market.

Quantitative, data-driven investing at the Pre-VC stage. We invest in capital-efficient technology startups with $5K–$30K+ MRR at $1.5M–$4M valuations. Fast decisions (one week), no gatekeepers, no BS.

Early-stage Latin American entrepreneurs solving critical healthcare, environmental, and societal challenges using science and technology. We provide capital, Silicon Valley networks, and operational expertise to build transformational companies.

EPIC Ventures backs early-stage technology companies building in the information economy, with a focus on enterprise SaaS, healthcare technology, cybersecurity, and future of work. The firm believes the best way to build lasting companies is through genuine partnership with founders — providing capital, strategic guidance, operational expertise, and deep network access. Founded in 1994, EPIC helped build the Utah tech ecosystem and continues to be the foundational VC of the Mountain West.

We back bold, ambitious, and resilient founders driving breakthrough innovations in HealthTech, CleanTech, and AgriFoodTech. Female-led and gender-mixed teams deliver superior returns and drive meaningful impact. Over five decades of combined experience navigating financial cycles enables us to partner authentically with founders, providing not just capital but strategic guidance and operational support.

Mundi backs bold, purpose-driven founders building technology companies at the intersection of deep tech and critical global challenges. Core thesis: Europe has world-class talent and ecosystem but suffers from a scale-up funding gap at growth stages. Kembara fund (€750M) bridges this by providing Series B/C growth capital to European deep tech and climate champions.

Montage Ventures aims to support radical thinkers who are bringing new ideas and platforms to foster change within the financial services, commerce and health sectors, leveraging AI as a key transformative agent.

We back MIT founders building deep-tech companies with defensible science or engineering advantages. We support the transition from researcher to founder, providing both capital ($500K-$5M) and operational support through the MIT ecosystem.

Founders building the possibly impossible deserve capital plus marketing support. Great technology combined with exceptional storytelling and narrative development creates world-changing moonshots. We provide both the capital and the story-telling expertise to help founders achieve escape velocity.

We invest in mission-critical infrastructure serving women and working families. Many essential systems have been dismissed as too complex or too human to solve, but technology and AI advances make transformation possible. This is a $1 trillion opportunity and generational economic growth driver.

Backs bold founders in technology and healthcare building companies that will define the future of their industries. Two practice areas: Enterprise/AI (AI infrastructure, frontier systems, cybersecurity, defense, fintech, developer tools) and Healthcare/Life Sciences (digital health, therapeutics, genomics, health system modernization). Deep partnership model, long-term patient capital approach across market cycles since 1969.

AI Eats Software. Over the next decade, virtually every bit of software will be replaced by artificial intelligence. We invest in founders and entrepreneurs who understand the transformational power of AI and are building solutions that reshape how we live, work, and play.

Supply Change Capital invests at the intersection of food, climate, and culture. We back early-stage technology transforming the food supply chain's foundational infrastructure - from supply chain resilience and logistics to health/nutrition innovation and labor automation. We believe the global food system ($10T industry) is least modernized sector globally, requiring urgent technological transformation to address climate impact (1/3 of GHG emissions), health crises (50%+ with diet-related chronic disease), and labor equity. We invest with dual lenses: climate impact (emissions reduction, soil health, biodiversity) and culture (supporting diverse founders who deliver 30% higher returns despite underinvestment). As former operators, we partner with founders not just with capital but operational expertise, impact metrics frameworks, and access to extensive advisor network of industry veterans.

Impact and profit are inseparable. We back visionary founders solving humanity's toughest problems in healthcare, AI, robotics, defense, and automation. We measure success in lives saved as well as returns.

CEE founders (Polish, Ukrainian, Romanian, etc.) are building the next generation of global software companies. We partner with experienced operators who combine deep industry expertise with serial entrepreneurship. Geographic arbitrage: exceptional technical talent in CEE with lower burn rates, global ambition. We provide early capital plus connections to Silicon Valley for follow-on funding (80% of portfolio follow-ons from SV/Europe/Asia). Goal: $500M+ exits in 8-10 years.

Back extraordinary entrepreneurs throughout the company-building lifecycle from seed to IPO. Combine venture capital expertise with BCG management consulting to accelerate value creation. Support founders with capital, strategic guidance, and access to global networks.

Gender-diverse teams produce superior returns on equity. We fund exceptional women-led startups where women hold meaningful operating C-suite roles and own substantial equity. Research shows companies with diverse female leadership are 39% more likely to be above-average profitable, 30% more likely to outperform, and 20% more likely to improve business outcomes.

We believe the greatest advancements of our lifetime will be the result of reprogramming chemistry and biology using creative technology platforms. We invest at the frontier of science, supporting founders re-architecting the world at a molecular level.

Deep tech startups at the edge of what is possible solve critical human and planetary health problems. SOSV backs founders combining scientific rigor with entrepreneurial grit, providing not just capital but access to specialized labs, manufacturing, and global expertise networks.

We refuse to compromise between doing good and delivering strong financial and commercial returns. Portfolio companies gain access to TELUS's commercial networks, data-rich platforms, and deep expertise across agriculture, health, and connectivity giving them a unique edge as they scale.

Early investors and long-term partners. We back exceptional founders solving real problems across sectors. When you hit a bump in the road, we're there solving problems alongside you with operational expertise and network leverage.

Extraordinary companies are built by driven founders whose mission to improve the health of people and planet is inseparable from their product. We partner with technical founders building technology solutions to the world's most important challenges across climate, health, biotech, and enabling technologies.

Social impact companies are undervalued at the earliest stages when metrics are unclear. We invest very early in mission-driven founders tackling the world's hardest problems, supporting them until they're attractive to top-tier VCs. 12-15 exceptional entrepreneurs can solve the largest global challenges.

Back outlier founders with unconventional ambition and deep-rooted urgency operating outside conventional wisdom. We believe the best companies are built by rare entrepreneurs who can filter out 95% of typical VC advice and construct exceptional talent and culture.

Investing at the intersection of for-profit and for-good. Companies that make the world better AND deliver strong financial returns. The Villain Test ensures both impact and profit alignment.

Expand the AI ecosystem by backing technology visionaries solving complex problems to reshape our world. Focus on game changers and market makers in AI, robotics, biotech, autonomous vehicles, and applied AI. Leverage NVIDIA's unique position as GPU infrastructure leader to identify and support companies that will drive adoption of NVIDIA technology.

Fund companies that help people live longer and live better through science and technology. We support exceptional technical founders solving real health and happiness problems with scientific rigor and consumer appeal. Our data-driven methodology and proprietary ML platform identify outsize return potential in complex early-stage companies.

Invest in century-defining technologies and companies. Focus on infrastructure-oriented, cross-vertical applied AI for physical-world and life-science problems, with deep healthcare systems expertise. Transform industries through foundational technology breakthroughs.

We invest in co-founding teams from research labs solving the most pressing challenges in science and technology. The most important aspect of deep tech companies is the founding team—we invest in technical founders with entrepreneurial spirit, not just ideas. We provide patient capital, deep technical mentorship, and access to UC Berkeley's innovation ecosystem and corporate networks.

Backing 'Venture Scientists' — PhD-trained technical founders applying rigorous scientific methodology to build transformative companies from fundamental research. Focus on deep tech and life sciences areas that address climate change, resource scarcity, and healthcare accessibility. Targets university spinouts and science-led startups in areas that are difficult to diligence for generalist investors.

The most valuable companies of our time will be the ones solving humanity's biggest problems across planetary health, human health, and economic health. We back exceptional founders building breakthrough solutions that create both financial returns and positive impact.

Permanent balance-sheet investor backing highly defensible, category-defining, mission-driven companies solving the world's biggest problems. Focus on founders transforming legacy industries with emphasis on diversity, equity, and inclusion.

Support passionate founders forging the future. Invest in seed and early-stage companies with unique ideas that have potential to reinvent entire industries. Focus on frontier technologies that make the world better and don't prey on human frailty.

Back entrepreneurs who think laterally and experiment across disciplines. We seek founders with multidisciplinary abilities who will become more insightful innovators. We value creative problem-solving, intellectual curiosity, and the ability to synthesize insights across fields.

Technology can have a highly disruptive impact on society. We back founders on the forefront of innovation with clear vision towards positive change, leveraging domain expertise to ensure value creation. Founder-first approach with operational support.

The best way to find and support AI companies is to be one ourselves. We back independent thinkers building real systems before consensus forms, partnering as radical learning partners from day one.

Women-led fund focused on healthcare infrastructure—middleware, payments, clinical trials, and data architecture—thesis-driven, GTM-heavy partner offering hands-on commercialization support for technical founders scaling into payer and provider markets.

As founder-operators, we see returns in relationships. We back ambitious founders with exceptional vision at the earliest stages with capital, mentorship, and network access.

Invest in companies addressing fundamental societal needs. Provide Talent/Capital/Attention platform via in-house content and advisory network. Mission-driven investments with specialized expertise in healthcare, climate, robotics, and deep tech.

The adverbs matter just as much as the verbs — how you build is as important as what you build. Exceptional people and character transform ideas into industry-shaping companies. We back extraordinary founders at pre-seed and seed who have unique insight into their market and the operational excellence to build in the right way.

Partner with visionary founders to turn bold ambitions into world-changing breakthroughs in life sciences, technology, healthtech, and crypto. Distinctive 'technical-risk-yes, regulatory-risk-no' filter ensures clear pathways to success.

Back founders with deep, first-hand domain expertise in specific industry verticals — those who have 'lived' the problem they are solving. Vertical-first software delivers faster time-to-value and stronger retention versus horizontal tools requiring heavy customization.

We back founders using technology to solve the world's biggest problems. We believe capitalism can be a force for good when companies are built to be both massively profitable AND create positive impact. The best entrepreneurs are determined, passionate, smart, creative, and can inspire thousands of talented people.

Mayfield invests in founders building iconic companies through AI-first innovation and human-AI collaboration. The firm believes the next wave of category-defining enterprises will leverage collaborative intelligence, where AI teammates augment and amplify human capability. Mayfield seeks deep tech founders with defensible innovation, clear market advantage, and the ability to scale globally.

Network effects are the #1 way to create defensibility in digital businesses. We invest in visionary founders building defensible businesses with network effects embedded in their core product.

Frontier technologies and medical breakthroughs offer the best opportunities to address fundamental human and environmental challenges. Diversity of founder backgrounds drives innovation and superior returns. Founders with domain expertise, technical credentials, and distinctive visions solve the world's biggest problems.

First women-led VC investing in underrepresented founders solving underserved problems in undercapitalized geographies. We capitalize on three biggest arbitrage opportunities: diversity of founders, geographic expansion beyond Silicon Valley, and problems with meaningful social impact. We back exceptional teams in consumer tech, digital health, and future of work sectors.

Partner with spiky founders building category-defining companies using novel technological approaches. Focus on AI-driven innovation across alternative architectures, custom software, research assistants, TechBio, infrastructure, and enterprise applications. Provide capital, operational support, strategic guidance, and network access for founders with unique insights and deep technical expertise.

Identify and invest in the world's top talent before they start a company. Build lifelong relationships through a proprietary university scout network at Stanford, MIT, Harvard, and other elite universities. Back exceptional founders within 1-3 years of graduation before they are widely recognized.

Great entrepreneurship exists everywhere—not just in traditional tech hubs. We invest in high-potential early-stage founders with a focus on underrepresented geographies (Midwest, Latin America) and demographics (women, minorities, immigrants). Beyond capital, we provide strategic guidance, ecosystem connections, and relocation support through our Tulsa-based infrastructure.

Backing transformative startups with exceptional defensibility and civilization-level impact potential. Focus on technical complexity, defensible innovation, and companies solving large-scale problems. Quality over volume approach with selective, thesis-driven investing.

Story invests in the building blocks of automated systems across three interconnected layers: sensory systems (data capture), data processing (organization and structure), and machine intelligence (applications and decision-making). We believe the most impactful problems require the most innovative solutions, and we partner with founders pursuing audacious, challenging businesses because that's what it takes to create lasting impact.

Women founders represent an overlooked asset class that delivers superior returns. Women-founded companies earn 26% more for investors, yet receive only 2% of venture funding. We invest exclusively in women-founded companies, providing capital, network access, and operational support to drive transformative change.

Partner with visionary founders to build category-defining companies in healthcare, enterprise software, fintech/insurtech, and deep technology. Provide deep operational support, board participation, and access to domain expert network. Focus on companies solving problems in regulated or data-rich industries. Leverage Allianz's unique vantage point on risk, data, and regulation to identify opportunities at intersection of innovation and regulatory necessity.

Breakthrough technologies and materials that power every AI chip, quantum computer, robot, battery, solar panel, biotech solution, and space exploration tool. Back founders who move beyond conventional industry boundaries to build bedrock economic infrastructure.

Partner with elite founders building transformational technologies that create lasting economic and societal value. Focus on Smart Enterprise across five sectors: Logistics, Life Sciences, Healthcare, IT Infrastructure, and Government/Defense. Invest in platforms that enable human experts to solve non-linear problems through data integration and network effects.

GV backs innovative founders moving the world forward, operating on long time horizons and dealing in decades, not rounds. Since 2023, GV has accelerated its focus on AI-native companies across infrastructure, applications, healthcare, and developer tools — with approximately 80% of new European investments now in AI.

Southern California's original seed-stage venture capital fund, focused on capital-efficient technology startups with differentiated competitive advantages targeting large, addressable and growing markets outside the Bay Area. Active, hands-on management with emphasis on venture fundamentals and disciplined investment strategy.

Invest in deep science and disruptive technology companies that solve fundamental human problems—inequality, health, climate adaptation. We back founders with vision, instinct, and drive to scale impact.

We democratize venture capital by providing individual accredited investors with professional-grade access to elite venture opportunities. We leverage our massive 850,000+ community network and 11,000+ investors to create unique value for founders, sourcing and diligencing deals alongside top-tier VCs (a16z, Sequoia, Khosla) without leading rounds. Our network is our competitive advantage—it compounds value for all stakeholders.

The most defensible companies are built on hard technology solving real problems at scale. We partner with technical founders leveraging deep domain expertise and the Tsinghua network to identify and nurture transformative innovations in deeptech, healthtech, and the data economy.

Humanizing deep tech by bringing advanced breakthrough technologies to where the people are and maximizing the value they generate for solving humanity's most critical crises. We invest in companies addressing climate, manufacturing labor shortages, healthcare costs, sustainable food production, and computing infrastructure.

Breakthrough technologies that stretch the imagination — deep tech with the potential to create new product categories. We bring company-building skills and operating expertise to help founders find product-market fit.

Invest in talented people solving challenging problems. We back extraordinary founders building products that people want with speed, efficiency, and operational excellence.

Boom Capital invests early in founders building at the frontiers of science. We position founders as scientist-protagonists and back highly technical teams tackling ambitious, non-obvious problems in genomics, machine intelligence, aerospace, new chemistries, and related deep science sectors.

We back outliers of the outliers - founders with unreasonable ambition who can filter out 95% of conventional VC advice. We seek category-defining companies aiming for $10B+ outcomes, not incremental improvements. Our conviction is deep, selective, and global. We don't meddle - we provide brutal honesty, talent upgrades, and capital for survival through near-death moments.

K5 Global backs category-defining companies from inception to IPO. The firm leverages exceptional networks across media, entertainment, politics, finance, and technology to provide strategic value beyond capital. We believe the best companies are built by founders who can access world-class talent, capital, and strategic relationships.

Exceptional founders living in the future deserve operators who provide more than capital. We partner with founders on go-to-market, brand, storytelling, and team building.

AI companies are built differently. We back the world's best AI native founders and help them reshape our world for the better. We go wide on product and deep on GTM.

Back technical teams working on breakthrough products. We invest in seed stage companies that demonstrate technical differentiation - meaning technical or product-level superiority is a major reason for future success. We pursue investments from application layer (AI/ML) through software infrastructure to hardware layers (semiconductors, photonics).

We invest in the Super Evolution—the convergence of ubiquitous sensors, advanced machine learning, cloud systems, robotics, 3D printing, and CRISPR. We partner with technical founders solving hard engineering and science problems to rethink large industries and tackle humanity's most pressing challenges.

We combine world-class AI analytics with industry-leading networks to identify exceptional companies and make rapid investment decisions. Great companies, regardless of sector or geography.

Invest in advanced technologies solving the world's greatest challenges in energy, environment, food safety, sustainable manufacturing, healthcare, and education. Back contrarian founders building capital-intensive, deep-tech ventures that address survival-driven global needs. Bridge breakthrough technologies from developed markets into emerging economies and vice versa. Create high-return, high-impact outcomes through hard technology.

Day 0 venture capital applied by a deep operator. Better Capital invests at the earliest stage where ambiguity is highest and operator judgment adds the most value. Solo GP model keeps conviction high and enables deep engagement with 20-25 companies at critical inflection points.

Back passionate, emerging talent solving deep technology challenges. Support founders from napkin-stage through IPO with patient, flexible evergreen capital. Focus on biotechnology, frontier software, food innovation, longevity, and AI that maximize impact and potential.

We back entrepreneurs using computational approaches (AI, simulation) to solve trillion-dollar problems in climate, health, industrial transformation, and national security. Deep tech requires patient capital and scientific rigor.

As the world becomes more information-rich, most transformative new companies will leverage data science, machine learning, and advanced computing power. We back founders building breakthrough solutions at this intersection.

We back technically ambitious founders building tomorrow's most iconic companies in frontier sectors like AI, hardtech, robotics, healthcare, and fintech. We believe great companies come from founders willing to tackle complex problems that generalist funds avoid.

Back purposeful entrepreneurs building scalable technology solutions for significant Latin American problems, with emphasis on inclusion, climate innovation, and business productivity while generating positive impact and strong returns.

AI-first venture capital firm investing in AI transformation and digital infrastructure across GenAI Infrastructure (AI chips, quantum, autonomous robotics), Deep Domains (fintech, healthcare, enterprise), and GenAI Agents (autonomous AI for real-world consumer and enterprise use).

Back wild hearts with the wildest ideas from the very beginning. Invest in companies, not rounds — following exceptional founders from pre-seed through all subsequent stages. Focused on ANZ founders building globally ambitious companies across any sector.

Founders backing founders. Swift invests in B2B AI and automation companies led by bold operators with a high Do:Say ratio, offering garage-to-IPO operating expertise from former company-builders.

Backs globally ambitious technology companies from pre-seed and seed through selected growth rounds using specialist EMEA sector teams and a platform model for capital, customers, talent, follow-on investors, and operational support.

NEA partners with ambitious founders at every stage of company building, from pre-seed through IPO. They invest at the intersection of technology and healthcare, believing the most transformational innovation occurs where deep domain expertise meets world-class technical founders. NEA serves as both capital provider and active operator.

Mubadala partners with world-class companies and institutions to drive transformational growth across strategic sectors and geographies. We believe in long-term value creation through patient capital, operational expertise, and global partnerships aligned with Abu Dhabi's economic diversification.

Backing the builders of the next layer of computing across AI infrastructure, defense, biotech, and American dynamism. Former 'Software is Eating the World' thesis evolved to 'AI is Eating Software'. Partners with technical founders building foundation models, cloud systems, and infrastructure for the AI era.

Back exceptional founders early, globally. Self-funded model enables founder-first alignment, rapid deployment, and direct support. We believe the best companies come from the best founders, regardless of background or current stage.

North Africa and Africa possess tremendous entrepreneurial talent. Strategic capital combined with operational expertise can unlock transformative solutions that reshape industries. We invest in founders solving region-critical problems.

Women receive only 2% of venture capital despite female-founded startups delivering 2x return per dollar vs. all-male teams. The Helm invests in game-changing, undervalued companies at seed stage founded by women, providing not just capital but operational support and ecosystem access.

We invest in the most promising entrepreneurs building the fastest-growing early-stage startups. We provide cross-border access by connecting founders to resources and networks across the world's most valuable and influential VC markets.

We are professional fixers for complex situations. An extension of your team. Fierce defenders when you need us most. Partners who roll up their sleeves. We invest in early-stage companies helping them avoid traditional roadblocks on their path to hypergrowth. We specialize in navigating hostile situations, IP protection, and crisis management.

Technology-based economic disruption of large markets through black swan investments. We seek founders with domain expertise and unreasonable conviction to build billion-dollar companies solving the world's largest problems.

AI-native companies where artificial intelligence is the core product and competitive moat, not just a feature. Three investment baskets: (1) AI infrastructure (vector databases, model serving, optimization), (2) vertical applications with 20%+ performance advantages, and (3) frontier research with clear commercialization paths.

Partner with exceptional founders to build generational companies that define the world's most critical industries. We provide not just capital but assemble teams of the highest caliber through our 5,000+ member builder community and deep operational expertise.

Backs DeepTech startups at the intersection of AI/ML, materials science, advanced manufacturing, biotechnology, optics, electronics, robotics, and blockchain — driving sustainable operational transformation across six thematics: transportation & logistics, energy & water, food & agriculture, fashion & beauty, precision medicine & aging, and retail & e-commerce. Requires commercial traction (min $1M revenue, 50%+ gross margins) and a minimum 10% ownership stake.

Exceptional founders backed at pre-seed and seed with both capital and hands-on operational support—talent, GTM, fundraising—build the most enduring companies. Pear is founder-first: founders-and-operators turned investors who have been in founders' shoes.

Back the quirky underdog pursuing seemingly impossible ideas. Frontier tech (aerospace, biotech, climate, robotics, crypto, AI, VR/AR) will create the next generation of legendary companies. Technical founders with deep domain expertise can solve the hardest problems in physics, chemistry, and computing.

Backing immigrant entrepreneurs building companies in Europe. Immigrants account for ~50% of US and ~40% of UK unicorns. NLV spots and supports this talent before the market catches up, investing unconditionally as the first check before lead VCs are in place.

We back dropouts, renegade students, and deep-tech scientists working on ideas that would appear in science fiction. We exist to prove that great founders don't need university degrees and are found in the oddest places. We invest at inception stage (R&D through Seed), providing capital, mentorship, community access, and operational support. People-first approach: it's more about the who than the what.

Back founders building iconic companies that transcend boundaries. We invest directly in their growth to make them unbreakable. Founded on principle that luck isn't made, it's engineered. Founders are our customer, not LPs. We always vote shares with founders and provide 1% non-dilutive founder development capital alongside every first check.

Back exceptional Kiwi founders building globally transformative companies, from day one to IPO. New Zealand founders represent a significantly undervalued asset class, and Icehouse provides capital plus an ecosystem of 3,000+ investors and deep operational support.

Extraordinary founders execute faster when isolated from distractions and provided intensive on-site support. We seek junkyard dogs with high agency, non-obvious vision, delusional optimism, and execution discipline. Category matters far less than founder quality.

Backing exceptional people at the very start of their journey. We support founders from inception to scale through our global residency programs, providing capital, mentorship, and access to a network of 1,500+ companies across six continents.

Sierra believes enterprise software is being fundamentally transformed by cloud computing and AI. They invest in technical founders building the next generation of enterprise solutions that deliver superior ROI through better efficiency, automation, and capability. The firm particularly focuses on infrastructure, security, healthcare innovation, and emerging deep tech.

Corporate-advantage seed investing. We identify promising AI and deep tech startups early, then leverage our hundreds of relationships with corporate venture capital arms to de-risk investments, accelerate time to exit, and create curated dealflow where both founders and corporates benefit from strategic alignment.

We help mission-driven pioneers win by harnessing the power of storytelling, art and culture. We back early-stage companies with customer obsession in their DNA and accelerate the mass adoption of technologies they create. Founders need more than capital—they need strategic support in building their narrative and leveraging media to accelerate adoption.

Invest in scalable, capital-efficient tech and tech-enabled startups at the Seed stage led by exceptional founders. We identify companies showing early traction that can achieve significant scale with disciplined capital deployment.

Emerson Collective invests in entrepreneurs and innovators driven by purpose, seeking consequential companies that deliver both generational impact and venture-scale returns. The firm targets sectors where biggest market opportunities meet meaningful impact levers: energy & environment, digital health, fintech, education, work, and media.

Data is the defensible moat in technology. We invest in companies that build proprietary data assets, analytics capabilities, or machine learning advantages to dominate their categories. Founded on 'information arbitrage' thesis - applying hedge fund quantitative discipline to early-stage venture.

AI is a milestone in data maturity progression, not a product category. Argonautic invests in founders building data-centric solutions across infrastructure (horizontal) and vertical markets. Multi-fund structure allows pre-seed to Series B deployment with unified thesis: recognizing verticals at different data adoption stages and deploying capital to those crossing inflection points into AI operationalization.

Founder-led seed fund investing at the intersection of healthcare/biotech and fintech, where GPs Linhao Zhang (Formation Bio, AI drug discovery) and Jake Cahan (January, fintech) bring deep operator experience to back early-stage founders in their domains.

Canaan invests in visionaries with transformative ideas across a 60/40 technology-to-healthcare split. The firm seeks early-stage companies with authentic founder passion, clear problem-solving value, and the potential to improve lives. Canaan runs a transparent, debate-driven partnership with deep operational expertise in healthcare regulation, biotech fundraising, and enterprise scaling.

We invest in the technologies that are transforming our lives, now and into the future. Founded by a successful entrepreneur and former tech journalist, Supernode backs exceptional founders building innovative technology companies across all sectors, from pre-seed through Series A and beyond.

First-check investors to exceptional founders building category-defining companies and to emerging venture funds reshaping the industry. Formation-stage specialists operating as partners from inception, not simply deploying capital.

We invest in mission-driven companies that dare to tackle impossible challenges, striving to transform industries and create lasting societal impact. We seek founders with audacity to dream big, resilience to persevere, and potential to build forever companies that shape human history.

HOF Capital invests in relentlessly ambitious founders building world-changing technologies that accelerate abundance: sustained technological progress that expands access to opportunity, health, and economic prosperity. Its current public thesis emphasizes AI and agentic systems as amplifiers of discovery, engineering, and knowledge creation, alongside frontier infrastructure and applications that can shorten scientific and technological invention timelines.

The only early-stage deep tech VC in CEE focusing on resilient technologies. We invest in founders building breakthrough technologies with proprietary IP in deep tech, MedTech, cleantech, autonomous vehicles/robotics, industrial, and resilient-tech. Technology must be genuinely unique and address real problems.

Backing exceptional, mission-driven entrepreneurs creating companies with Massively Transformative Purpose (MTP) that impact billions of people. We invest across the full innovation lifecycle, from early-stage frontier technology through scale to liquidity. We love companies and individuals that are different, fishing where others aren't, seeking opportunities where exceptional visionary entrepreneurs see novel paths to greatness.

Early-stage venture capital for IT and Biotech companies in Colorado Front Range and Mid-Atlantic. Focus on experienced founding teams solving important problems with potential for significant financial returns. Patient capital approach with operational support and deep regional networks.

Invest in bold, visionary founders building transformational businesses long before the world believes in them. We back founders solving impossible-seeming problems across frontier sectors: AI/robotics, crypto, biotech, aerospace, and unconventional ideas.

We invest in technical breakthroughs that overcome the world's greatest challenges. We partner at inception with technically brilliant dreamers who see past impossible to inevitable. We evaluate scientific opportunities through both commercial potential and human impact lenses.

We invest in companies organized around five concrete objectives: improving worldwide health and happiness, promoting resource sustainability, increasing human potential and productivity, increasing knowledge/empathy/connectedness, and disrupting industries that resist these goals. We operate as both investors and company-builders, providing operational expertise and hands-on support far beyond capital.

Sand Hill Angels backs seed-stage, high-tech companies with large and growing markets, well-defined problems, disruptive solutions, defensible technology, and strong teams with demonstrated ability to execute. The group leverages 145+ experienced angels to provide capital, mentorship, and network access across the Silicon Valley ecosystem.

Back ambitious teams with strong learning and execution capacities across all sectors, stages, and geographies. Technology-enabled businesses preferred. Volume-based, founder-centric investment philosophy.

We build category-defining companies through a combination of design, product, operations, and capital. We identify market gaps, pair brilliant founders with Expa's studio resources, and help them build companies that reshape entire industries.

Backing the best founders, not just the best-connected. We assess founders on their qualities, not CV or past experience. We focus on founders building solutions for climate equity, economic empowerment, and healthy ageing.

A majority of the data our brains analyze is visual. Therefore, the majority of the data AI will analyze will also be visual, spanning the light and electromagnetic spectrums across all sectors. We thrive on collaborating with deep technical teams who leverage computer vision, machine learning and artificial intelligence to analyze visual data.

Investing in the picks and shovels of volatility caused by convergent forces (AI, Web3, Deep Science) intersecting with demographic shifts and climate change. We seek to create venture-scale returns by backing bold founders building more equitable, beneficial, transparent, and accessible structures.

High-growth early-stage companies with disruptive innovation across diversified sectors. Particular focus on underserved communities and Rocky Mountain region. Platform approach with multiple themed funds for specialized strategies.

Lead pre-seed and seed rounds in Canadian B2B software and AI-enabled vertical workflow companies with an initial product in market, early product-market-fit signals, and ambition to scale across North America or globally.

Elevate Ventures partners with innovation-driven founders to provide strategic capital, mentorship, and ecosystem access. Founded by a former founder (Governor Mitch Daniels), the firm believes the best founders exhibit grit, creativity, and coachability. They invest across all sectors and geographies but maintain primary focus on Indiana and Great Lakes Region entrepreneurs building cross-sector innovations.

We invest in early-stage Polish deep tech startups with a clear technological edge—solving hard problems through software-driven or hardware-enabled solutions. Defensible technology, early validation, and resilient founders are non-negotiables. A deeptech project without real customers becomes a research project.

The primary constraint for seed-stage, science-based entrepreneurs is access to experienced business judgment. CDL provides objective-based mentoring from accomplished entrepreneurs, angels, and scientists to help founders prioritize tasks and de-risk their businesses.

Emerging hardware founders are overlooked by traditional VC. By combining capital with hands-on manufacturing expertise, infrastructure access, and operational support, we unlock value for founders building tech you can touch.

Rule30 uses a fully algorithmic decision engine to identify outlier founders at pre-seed and seed stages across Europe and North America. The fund removes human bias by analyzing founder experience, educational background, network evolution, and career trajectory — excluding names and photos. The algorithm ranks founders into top 10%, 3%, and 0.1% tiers. An index-style strategy of 75-85 bets targets ≥3x minimum returns with 97.5% confidence.

We partner with entrepreneurs from their early days through every stage of growth, focusing on innovative solutions in technology, healthcare, and financial services.

Great startups can be built anywhere. We believe in founder-centric investing with operational support from a team of successful founders. We serve undernetworked geographic regions.

Backs European pre-seed and seed founders building technologies for Energy, Industry, and Resilience, especially energy transition, industrial automation, practical AI for infrastructure, manufacturing, logistics, energy grids, and critical systems.

Equity of access and representation in venture capital delivers positive returns. Diverse and underrepresented (including LGBTQ+) leaders of high-growth companies deserve capital access. When these founders succeed, they influence ecosystems and open doors for historically excluded groups.

MaC backs visionary founders building category-defining companies with deep understanding of cultural shifts, technological advancements, and emerging market trends. Founders must demonstrate authentic insight into why their problem needs solving now, combined with ability to see how the world is changing. Particular focus on founders paying attention to shifts others might miss.

Startups positioned as transformation partners with Fortune 500 corporates create the most impactful solutions. We believe the next generation of market leaders will emerge through collaborative innovation between startups and incumbent enterprises, supported by global expertise and capital.

Leverage creator economy and influencer networks to add tangible value to early-stage companies. Invest in ambitious Gen Z founders building consumer products with high influencer marketing potential. Influencer partners actively support portfolio companies with marketing, business development, and strategic partnerships.

Back the world's most ambitious and transformative entrepreneurs capable of building world-defining companies over 20+ years. Invest in founders with independent thought and first-principles vision to solve humanity's biggest problems across all sectors and geographies.

Democratize access to venture capital by building large syndicates of non-traditional LPs. Invest across all stages, sectors, and geographies based on founder quality and market conviction, not category restrictions. Enable 2,000+ diverse co-investors to participate alongside marquee firms like Sequoia and Andreessen Horowitz while maintaining founder-friendly economics.

Invest in early-stage tech companies addressing world's largest market opportunities and solving humanity's biggest challenges. Leverage global distributed team to source, evaluate, and support transformational founders.

Operator-led fund investing in ambitious founders building transformative AI applications. We partner with technical founders who understand AI/ML deeply and are solving real customer problems with capital efficiency. Great product is always the best marketing.

Exceptional founders applying unique talents and backgrounds to produce disruptive and differentiated products and services. Minimum $500K ARR at entry. Generalist across AI, B2B SaaS, logistics, healthcare, and advanced manufacturing.

IGC pioneered the Reverse VC™ model — starting with corporate demand rather than capital deployment. Their ReverseVision platform identifies what Global 5000 companies want to buy, then matches emerging tech founders to those demand signals. Investment flow: Demand → Commercialization → Valuation → Capital → Exit. This approach claims higher success rates, better deal terms, and reduced downside risk by replacing intuition with engineered outcomes.